Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of fusaric acid and paclitaxel or carboplatin

Cancer Letters

Volumn 243, Issue 1, 2006, Pages 58-63

  Jaglowski, Jeffrey R ^a   Stack Jr , Brendan C ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Carboplatin; Chemotherapy; Fusaric acid; Head and neck cancer; HNSCC; Paclitaxel

Indexed keywords

CARBOPLATIN; FUSARIC ACID; PACLITAXEL;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOMA CELL; CELL COUNT; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FUSARIC ACID; GROWTH INHIBITORS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MOUTH NEOPLASMS; NUCLEIC ACID SYNTHESIS INHIBITORS; PACLITAXEL; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 33749236953     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.11.028     Document Type: Article

References (39)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics, 2004. CA Cancer J. Clin. 54 1 (2004) 8-29
2. Parkin D.M., Pisani P., and Ferlay J. Global cancer statistics. CA Cancer J. Clin. 49 (1999) 33-64
3. Shah J.P., and Lydiatt W. Treatment of cancer of the head and neck. CA Cancer J. Clin. 45 6 (1995) 352-368
4. Forastiere A.A., Shank D., Neuberg D., Taylor IV S.G., DeConti R.C., and Adams G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 82 11 (1998) 2270-2274
5. Leyvraz S., Ohnuma T., Lassus M., and Holland J.F. Phase 1 study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion. J. Clin. Oncol. 3 10 (1985) 1385-1392
6. Shin D.M., Khuri F.R., Glisson B.S., Ginsberg L., Papadimitrakopoulou V.M., Clayman G., et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91 7 (2001) 1316-1323
7. Vokes E.E., Haraf D.J., Stenson K., Stupp R., Malone D., Levin J., et al. The role of paclitaxel in the treatment of head and neck cancer. Semin. Oncol. 22 (1995) 8-12 (5 Suppl 12)
8. Schiff P.B., and Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl Acad. Sci. USA 77 3 (1980) 1561-1565
9. Cortes-Funes H., and Aisner J. Paclitaxel in head and neck cancer and other tumor types: chairmen's introduction. Semin. Oncol. 24 (1997) S2-51-S2-57 (1 Suppl 2)
10. Forastiere A.A., and Urba S.G. Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin. Oncol. 22 (1995) 24-27 3 Suppl 6
11. Holmes F.A., Walters R.S., Theriault R.L., Forman A.D., Newton L.K., Raber M.N., et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl Cancer Inst. 83 24 (1991) 1797
12. Hussain M., Gadgeel S., Kucuk O., Du W., Salwen W., and Ensley J. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 86 11 (1999) 2364-2369
13. J.R. Jaglowski, I.S. Zagon, B.C. Stack Jr., M.F. Verderame, A.E. Leure-Dupree, J.D. Manning, et al., Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck, Cancer. Chemother. Pharmacol. Jul. 56 (1) (2005) 97-104.
14. McLaughlin P.J., Jaglowski J.R., Verderame M.F., Stack Jr. B.C., Leure-Dupree A.E., and Zagon I.S. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. Int. J. Oncol. 26 3 (2005) 809-816
15. Chabner B.A., and Collins J.M. Cancer Chemotherapy: Principles and Practice (1990), Lippencott/Williams & Wilkins, Philadelphia, PA
16. Eisenberger M., Hornedo J., Silva H., Donehower R., Spaulding M., and Van Echo D. Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J. Clin. Oncol. 4 10 (1986) 1506-1509
17. Ganger D.R., Hamilton P.D., Fletcher J.W., et al. Metallopanstimulin is overexpressed in a patient with colonic carcinoma. Anticancer Res. 17 3C (1997) 1993-1999
18. Rapella A., Negrioli A., Melillo G., et al. Flavopiridol inhibits vascular endothelia growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. Int. J. Cancer 99 (2002) 658-664
19. Semenza G.L. Hypoxia-inducible factor1 and the molecular physiology of oxygen homeostasis. J. Clin. Lab. Med. (1998) 131207-131214
20. Yuan Z., Huang X., Zhang W., et al. Cloning and characterization of a novel zinc finger protein (MDZF) that is associated with monocytic differentiation of acute promyelocytic leukemia cells. J. Cancer. Res. Clin. Oncol. 127 (2001) 659-667
21. Medici N., Abbondanza C., Nigro V., et al. Identification of a DNA binding protein cooperating with estrogen receptor as RIZ (retinoblastoma interacting zinc finger protein). Biochem. Biophys. Res. Commun. 264 (1999) 983-989
22. Kalenik J.L., Chen D., Bradley M.E., et al. Yeast two-hybrid cloning of a novel zinc finger protein that interacts with the multifunctional transcription factor YY1. Nucleic Acids Res. 25 (1997) 843-849
23. Merchant J.L., Iyer G.R., Taylor B.R., et al. ZBP-89, a Kruppel-like zinc finger protein, inhibits epidermal growth factor induction of the gastrin promoter. Mol. Cell. Biol. 16 (1996) 6644-6653
24. Grondin B., Bazinet M., and Aubry M. The KRAB zinc finger gene ZNF74 encodes an RNA-binding protein tightly associated with the nuclear matrix. J. Biol. Chem. 271 (1996) 15458-15467
25. Brazas R.M., Bhoite L.T., Murphy M.D., et al. Determining the requirements for cooperative DNA binding by Swi5p and Pho2p (Grf10p/Bas2p) at the HO promoter. J. Biol. Chem. 270 (1995) 29151-29161
26. Alonso J.C., Stiege A.C., Dobrinski B., et al. Purification and properties of the RecR protein from Bacillus subtilis 168. J. Biol. Chem. 268 (1993) 1424-1429
27. Opipari Jr. A.W., Boguski M.S., and Dixit V.M. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J. Biol. Chem. 265 (1990) 14705-14708
28. Stack Jr. B.C., Hansen J.P., Ruda J.M., Jaglowski J., Shvidler J., and Hollenbeak C.S. Fusaric acid: a novel agent and mechanism to treat HNSCC. Otolaryngol. Head Neck Surg. 131 1 (2004) 54-60
29. Wang H., and Ng T.B. Pharmacological activity of fusaric acid (5-butylpicolinic acid). Life Sci. 65 (1999) 849-856
30. Nadgornaya N.I., Barchtein U.S., and Kurbastskaya Z.A. Disruptive effect of various mycotoxins on the mitotic regime of Her-2 cells. Mikrobiol. Z. 43 (1981) 114-118
31. Fernández-Pol J.A., and Jonson G.S. Selective toxicity induced by picolinic acid in simian virus 40-transformed cells in tissue culture. Cancer Res. 37 (1977) 4276-4279
32. Fernández-Pol J.A. Iron: possible cause of the G1 arrest induced in NRK cells by picolonic acid. Biochem. Biophys. Res. Commun. 78 (1977) 136-143
33. McLaughlin P.J., Levin R.J., and Zagon I.S. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. Int. J. Oncol. 14 5 (1999) 991
34. Leonard C.E., Chan D.C., Chou T.C., Kumar R., and Bunn P.A. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res. 56 22 (1996) 5198-5204
35. Leonard C.E., Chan D.C., Chou T.C., Kumar R., and Bunn P.A. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res. 56 22 (1996) 5198-5204
36. Srivastava R.K., Srivastava A.R., Korsmeyer S.J., Nesterova M., Cho-Chung Y.S., and Longo D.L. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell Biol. 18 6 (1998) 3509-3517
37. Fernandez-Pol J.A., Klos D.J., and Hamilton P.D. Cytotoxic activity of fusaric acid on human adenocarcinoma cells in tissue culture. Anticancer Res. 13 (1993) 57-64
38. Ogata S., Inoue K., Iwata K., et al. Apoptosis induced by picolinic acid-related compounds in HL-6 cells. Biosci. Biotechnol. Biochem. 65 (2001) 2337-2339
39. J.M. Ruda, K.S. Beus, C.S. Hollenbeak, R.P. Wilson, B.C. Stack Jr., The effect of fusaric acid (FA) on the growth of subcutaneously xenografted scc-1 cells in a nude mouse model. J. Investig. New Drugs, in press.